Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities
Top industry leaders and venture firms unite behind Ukko's efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten
PALO ALTO, Calif., TEL AVIV, Israel and LEVERKUSEN, Germany, Jan. 27, 2021 -- (Heal... Biopharmaceuticals, Venture Capital Ukko, Bayer, food allergy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Allergy | Allergy & Immunology | Food Allergy | Funding | Germany Health | Gluten | Israel Health | Middle East Health | Peanuts | Pharmaceuticals | Venture Capital